☰

Lukas Baitsch, Ph.D. - Publications

Affiliations: 
Cancer Biology Dana-Farber Cancer Institute, Boston, MA, United States 
Tree Info Similar researchers PubMed Report error

14 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Wang Y, Li YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, et al. Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. Elife. 7. PMID 29528283 DOI: 10.7554/Elife.36414  0.557
2015 Yuzugullu H, Baitsch L, Von T, Steiner A, Tong H, Ni J, Clayton LK, Bronson R, Roberts TM, Gritsman K, Zhao JJ. A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Nature Communications. 6: 8501. PMID 26442967 DOI: 10.1038/Ncomms9501  0.497
2014 Li N, Fassl A, Chick J, Inuzuka H, Li X, Mansour MR, Liu L, Wang H, King B, Shaik S, Gutierrez A, Ordureau A, Otto T, Kreslavsky T, Baitsch L, et al. Cyclin C is a haploinsufficient tumour suppressor. Nature Cell Biology. 16: 1080-91. PMID 25344755 DOI: 10.1038/Ncb3046  0.515
2014 Wang Y, Lee YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, et al. MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. Elife. 3: e01763. PMID 24844244 DOI: 10.7554/Elife.01763  0.552
2014 Yuzugullu H, Baitsch L, Steiner A, Clayton LK, Gritsman K, Zhao JJ. Abstract 4775: PI3K-p110β is required for leukemic transformation and HSC depletion in the absence of Pten Cancer Research. 74: 4775-4775. DOI: 10.1158/1538-7445.Am2014-4775  0.48
2013 Hebeisen M, Baitsch L, Presotto D, Baumgaertner P, Romero P, Michielin O, Speiser DE, Rufer N. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. The Journal of Clinical Investigation. 123: 1044-56. PMID 23391724 DOI: 10.1172/Jci65325  0.424
2012 Gupta B, Iancu EM, Gannon PO, Wieckowski S, Baitsch L, Speiser DE, Rufer N. Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 488-501. PMID 22735807 DOI: 10.1097/Cji.0B013E31826183A7  0.418
2012 Baitsch L, Fuertes-Marraco SA, Legat A, Meyer C, Speiser DE. The three main stumbling blocks for anticancer T cells. Trends in Immunology. 33: 364-72. PMID 22445288 DOI: 10.1016/J.It.2012.02.006  0.443
2012 Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher H, Rufer N, Matter M, Michielin O, Speiser DE. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. Plos One. 7: e30852. PMID 22347406 DOI: 10.1371/Journal.Pone.0030852  0.425
2012 Baumgaertner P, Jandus C, Rivals JP, Derré L, Lövgren T, Baitsch L, Guillaume P, Luescher IF, Berthod G, Matter M, Rufer N, Michielin O, Speiser DE. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. International Journal of Cancer. Journal International Du Cancer. 130: 2607-17. PMID 21796616 DOI: 10.1002/Ijc.26297  0.426
2011 Speiser DE, Wieckowski S, Gupta B, Iancu EM, Baumgaertner P, Baitsch L, Michielin O, Romero P, Rufer N. Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. Proceedings of the National Academy of Sciences of the United States of America. 108: 15318-23. PMID 21876175 DOI: 10.1073/Pnas.1105419108  0.433
2011 Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, Rufer N, Speiser DE. Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. The Journal of Clinical Investigation. 121: 2350-60. PMID 21555851 DOI: 10.1172/Jci46102  0.376
2011 Salaun B, Yamamoto T, Badran B, Tsunetsugu-Yokota Y, Roux A, Baitsch L, Rouas R, Fayyad-Kazan H, Baumgaertner P, Devevre E, Ramesh A, Braun M, Speiser D, Autran B, Martiat P, et al. Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. Journal of Translational Medicine. 9: 44. PMID 21507256 DOI: 10.1186/1479-5876-9-44  0.37
2009 Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Research. 69: 8085-93. PMID 19808957 DOI: 10.1158/0008-5472.Can-09-2226  0.389
Show low-probability matches.